Company / Operating Cash Flow per Share
Travere Therapeutics, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$0.43
FY2025
5-year range
-$4.36 / $0.43
FY2021-FY2025
Trend
+113.7%
vs FY2024
Sector context
#66 of 212
Health Care
What the data says
At $0.43, Travere Therapeutics, Inc.'s operating cash flow per share ranks #66 of 212 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-4.36 in FY2023 to $0.43 in FY2025.
Based on SEC 10-K filings.
0.43 in FY2025.
Improved from $-4.36 to $0.43 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#66 of 212 in Health CareTop 31% of 212This company $0.43 Sector average -$14.72
▼
+102.9% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 113.7% year-over-year.
- Ranks #66 out of 212 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.43 | +113.7% |
| FY2024 | -$3.15 | +27.7% |
| FY2023 | -$4.36 | -46.1% |
| FY2022 | -$2.98 | -167.6% |
| FY2021 | -$1.11 | -92.4% |
| FY2020 | -$0.58 | -423.8% |
| FY2019 | $0.18 | +304.7% |
| FY2018 | -$0.09 | -138.5% |
| FY2017 | -$0.04 | +97.1% |
| FY2016 | -$1.26 | -2257.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026